title: Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury.
abstract: Progressive ischemia and necrosis of the skin following thermal injury are reduced by postburn administration of the steroid hormone dehydroepiandrosterone (DHEA). Thermally injured animals were provided with a subcutaneous injection of DHEA, or a related species of steroid hormone, at various times after burning. During the 96 hr following administration of the scald burn, tissue necrosis was closely monitored. Subcutaneous administration of DHEA at approximately 1 mg/kg/day achieved optimal protection against the development of progressive dermal ischemia. DHEA, 17 alpha-hydroxy-pregnenelone, 16 alpha-bromo-DHEA, and androstenediol each demonstrated, a similar level of protection. Other forms of steroids, including DHEA sulfate, androstenedione, 17 beta-estradiol, or dihydrotestosterone, exhibited no protective effect under the conditions tested. Additionally, intervention therapy with DHEA could be initiated up to 4 hr, but not 6 hr, after burn without a marked reduction in therapeutic benefit. Examination of the microvasculature of thermally injured dorsal skin suggested that postburn intervention with DHEA, either directly or indirectly, maintained a normal architecture in most of the dermal capillaries and venules within burn-exposed tissue. These findings suggest that systemic intervention therapy of burn patients with DHEA or a similar acting steroid hormone may be useful in preventing the progressive tissue destruction caused by progressive ischemia.
authors.affiliation: Department of Pathology, University of Utah School of Medicine, Salt Lake City 84132, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Araneo
authors.forename: S Y
authors.initials: SY
authors.lastname: Ryu
authors.forename: S
authors.initials: S
authors.lastname: Barton
authors.forename: R A
authors.initials: RA
authors.lastname: Daynes
mesh_terms: D006907:17-alpha-Hydroxypregnenolone / Q000627:therapeutic use; D000734:Androstenediols / Q000627:therapeutic use; D000818:Animals; D001415:Back; D002056:Burns / Q000150:complications* / Q000473:pathology; D003687:Dehydroepiandrosterone / Q000627:therapeutic use*; D013196:Dihydrotestosterone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004423:Ear; D004958:Estradiol / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009336:Necrosis; D011897:Random Allocation; D012867:Skin / Q000098:blood supply* / Q000473:pathology; D013997:Time Factors
chemical_list: D000734:Androstenediols; D013196:Dihydrotestosterone; D006907:17-alpha-Hydroxypregnenolone; D003687:Dehydroepiandrosterone; D004958:Estradiol